Dr. Yufang Hu possesses extensive skills and knowledge in the Industrial Pharmaceutical field with over 30 years of experience in organizational development and management. He has also successfully led and collaborated on multiple international business operation projects with relevant entities. From 1999 to 2023, he served as senior Senior Vice president in TTY Biopharm Co. Ltd., Taiwan, and one of key responsibilities is to develop the company's product line. It should be noted that he also established the liposome technology and long-acting microsphere injection platforms, including generic Lupron Depot® (Leuprolide Acetate for Depot Suspension), generic Risperdal Consta® (Risperidone Long-Acting Injection), generic Sandostatin LAR® Depot (Octreotide Acetate for Injectable Suspension); and launched the AmBisome generic drug (Liposomal Amphotericin B Injection) in the world, as well as obtained the global contract manufacturing project from Johnson & Johnson for Doxil (Liposomal Doxorubicin Injection) product.

It must be mentioned that Dr. Hu is one of the inventors of Onyvide® (Liposomal Irinotecan Injection). Owing to his pivotal role in its development, he served as the President and CEO of PharmaEngine Inc. from 2019 to 2022, the company responsible for bringing the product to market. In 2017, Dr. Hu founded EnhanX Biopharm Inc., a company focused on developing liposomal therapies for multiple sclerosis, where he continues to serve as Chairman. In 2023, he established Genext Biopharm Limited, a biotechnology company dedicated to the development of nucleic acid therapeutics. Genext leverages Lipid Nanoparticle (LNP) technology as its core drug delivery platform. Dr. Hu currently serves as the CEO of the company.

Dr. Hu graduated from the Pharmacy Department of Kaohsiung Medical University with a bachelor's degree and passed the Taiwan Pharmacist National Examination to become a professional pharmacist. After graduating from university, He went to St. John’s University School of Pharmacy in New York State, USA, to obtain a master’s degree and a doctoral degree in pharmaceutical engineering. After receiving his Ph.D., he worked as a Scientist at Bristol Myers Squibb in New Jersey, USA. In 1999, at the invitation of Mr. Rongjin Lin, the then chairman and general manager of TTY Biopharm Co. Ltd, he returned to Taiwan and joined TTY Biopharm. Currently, he is participating in multiple important pharmaceutical associations holding director positions, such as The Pharmaceutical Society of Taiwan, Control Release Society Taiwan Chapter, and Institute of Engineering Education Taiwan. In 2009, Dr. Hu won the International Who’s Who Laureate; in 2011, received The Silver Invention Award of the R.O.C. National Inventor Prize.